REGISTER
The Inaugural Huashan Awards: Establishment and Evaluation Framework

On December 21, the Expanded Meeting of the Management Committee of the Inaugural Huashan Awards for Innovative Drugs in China, together with a seminar on evaluation criteria and procedures, was held in the Yangpu District, Shanghai. Members of the Huashan Awards Management Committee and the Expert Review Committee attended the meeting and provided recommendations on the evaluation standards and review process for the first edition of the awards.


Representatives of the Organizing Committee introduced the overall award framework, evaluation criteria, and review procedures. The Huashan Awards are jointly initiated by MedJ and Tonacea, with a focus on professional standards, international benchmarks, independent evaluation, and Chinese innovation models. The awards aim to identify value-based benchmarks among China’s innovative drugs and biopharmaceutical enterprises.

The Huashan Awards comprise five categories, including two drug-focused awards—Best Clinical Value Medication and Best Breakthrough Medication—and three enterprise-focused awards—Best Innovative Big Pharma, Best Innovative Growing Biopharma, and Best Innovative Rising Biotech.

The evaluation process consists of three independent stages: data-based screening, expert review, and final assessment by the Management Committee. Quantitative indicators are applied using publicly available and reliable industry databases. Based on scoring results, 6–8 candidates are shortlisted for each category and submitted to the Expert Review Committee for further evaluation. Approximately 50% of candidates advance to the nomination stage, after which the Management Committee conducts the final review and selects 0–3 awardees per category.

Each stage operates independently, and both expert reviewers and the Management Committee may only veto candidates rather than nominate new ones, ensuring objectivity, fairness, and independence throughout the process.

0
0
Loading